Device Trial Radar · NCT06847542
A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
250
Planned (sponsor's estimate)
Start
Nov 27, 2025
Primary completion
Nov 15, 2028
Study completion Nov 15, 2028
Sponsor
- Lead sponsor
- Hoffmann-La RocheNot on our public-company list
- Sponsor type
- Industry
- Collaborators
- Genentech, Inc.
- First posted
- Feb 26, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the effectiveness, safety, and PROs of the port delivery system with ranibizumab 100 milligrams/milliliters (mg/mL) refilled every 36 weeks (Q36W) in participants with nAMD.
Conditions
- Neovascular Age-related Macular Degeneration
Interventions
Susvimo PDS ImplantDevice
Ranizumab will be administered via a PDS implant per the schedule described in the arm.
RanibizumabDrug
Participants will receive ranibizumab delivered through the PDS implant. Participants will receive ranibizumab, 0.5 mg IVT injections as a supplemental treatment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Best Corrected Visual Acuity (BCVA) Score Averaged Over Weeks 68 and 72, as Assessed Using the Early Treatment Diabetic Retinopathy Study (ETDRS) Chart at a Starting Distance of 4 MetersTime frame: Baseline, Week 68, Week 72
Locations
64 sites in 13 countries. Site status is shown where the registry gives one.
Medizinische Universität Innsbruck
Innsbruck, Austria · Recruiting
Kepler Universitätskliniken GmbH - Med Campus III
Linz, Austria · Recruiting
Landesklinikum Mistelbach
Mistelbach, Austria · Recruiting
61 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.